FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Metadata listed "Fennec Pharmaceuticals Inc." but the filing text identifies Adherex Technologies Inc.)
Reporting Date: February 21, 2007
Event: Completion of a public offering of units and a change in regulatory status from a "foreign private issuer" to a U.S. domestic issuer.

Key Financial Metrics

• Gross Proceeds Raised: US$25,000,000
• Units Issued: 75,759,000 units
• Price Per Unit: US$0.33
• Underwriter Commission: US$1,500,000 (6% of gross proceeds)
• Common Shares Issued: 75,759,000 shares
• Warrants Issued to Investors: 37,879,500 (representing half a warrant per unit)
• Warrant Exercise Price: US$0.40 per share
• Warrant Expiration: Three years from closing
• Underwriter Warrants: 4,545,540 units (same structure as investor units)

Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.

Material Changes

• Regulatory Status Change: Adherex is no longer a "foreign private issuer" because more than 50% of its outstanding shares are now owned by U.S. residents. It is now subject to all reporting requirements applicable to U.S. domestic issuers.
• Ownership Structure: Significant concentration of ownership occurred among three entities following the offering:

Percentages assume the exercise of all warrants issued to each entity.

Outlook, Risks, and Management Commentary

• Capital Deployment: The company raised capital to support operations, though specific strategic use of funds is not detailed in this excerpt.
• Future Dilution: The issuance of warrants to investors and the underwriter creates potential future dilution if exercised at the US$0.40 strike price.
• Compliance: The shift to U.S. domestic issuer status increases regulatory reporting obligations.
• Management Relations: The company states it has no arrangements with the three major new shareholders regarding the election of directors or other matters.

Investor Verification Checklist

• Verify the exact amount of net proceeds available for operations after deducting the US$1.5 million underwriting fee and other transaction costs.
• Confirm the total number of outstanding shares and warrants post-offering to assess full dilution impact.
• Review the company's cash position and burn rate to determine how long the US$25 million will sustain operations.
• Monitor the company's transition to U.S. domestic reporting standards for any changes in disclosure frequency or content.
• Check for any subsequent filings regarding the exercise of the underwriter's warrants or the investor warrants.